Art. -Nr.: HY-18939

N6-Cyclohexyladenosine

(Synonyms: CHA)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC₅₀ = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.79%
CAS. Nr.: 36396-99-3
Formel: C₁₆H₂₃N₅O₄
Molecular Weight:349.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

N6-Cyclohexyladenosine Chemical Structure

CAS. Nr.: 36396-99-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Adenosine Receptor Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	GI₅₀	>250 μM Compound: 16, CHA	Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay	[PMID: 18588281]
HT-29	GI₅₀	>250 μM Compound: 16, CHA	Antitumor activity against human HT29 cells after 48 hrs by MTS assay Antitumor activity against human HT29 cells after 48 hrs by MTS assay	[PMID: 18588281]
K562	GI₅₀	>250 μM Compound: 16, CHA	Antitumor activity against human K562 cells after 48 hrs by MTS assay Antitumor activity against human K562 cells after 48 hrs by MTS assay	[PMID: 18588281]
MCF7	GI₅₀	>250 μM Compound: 16, CHA	Antitumor activity against human MCF7 cells after 48 hrs by MTS assay Antitumor activity against human MCF7 cells after 48 hrs by MTS assay	[PMID: 18588281]

In Vitro

N6-Cyclohexyladenosine reduces the extent of demyelination and promote remyelination in rat optic chiasm^[1].
N6-Cyclohexyladenosine (10 nM-50 μM; 20 h) significantly increases the secretion of Erythropoietin in human hepatoma cell line Hep 3B under hypoxic conditions^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

N6-Cyclohexyladenosine (2 μL, 1%; injected inside the right lateral ventricle; administered daily during the demyelination phase (days 0-13) or the remyelination phase (days 14-27)) in a rat optic chiasm demyelination model can reduce the extent of demyelination, promote remyelination, and improve visual evoked potential-related indicators^[1].
N6-Cyclohexyladenosine (10-100 μM; infused into the basal forebrain via a microdialysis probe) can induce sleep in a rat model of basal forebrain cholinergic neuron injury ^[2].
N6-Cyclohexyladenosine (60 μg/kg; i.p.) is a potent locomotor depressant in mice^[3].
N6-Cyclohexyladenosine (6.25 nM/1 μL; intrastriatal injection; single) attenuates neuronal death and improves cognitive and motor deficits in a rat model of Huntington's disease induced by 3-NP^[6].
N6-Cyclohexyladenosine (1.5 mg/kg induction dose, followed by three 1.0 mg/kg doses every 6 hours for a total of 4 doses; i.p.; 4 times) does not show neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), failing to reduce infarct volume and improve neurological function^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Sprague-Dawley rats (weight 180-220 g), 3-nitropropionic acid (3-NP)-induced Huntington's disease model^[6]
Dosage:

6.25 nM/1 μL (dissolved in DMSO)
Administration:

Intrastriatal injection, single administration, 45 min after 3-NP injection
Result:

Significantly attenuated neuronal death in the striatum.
Improved cognitive and motor deficits as shown by increased time spent in the target quadrant in the Morris Water Maze test and increased fall off latency in the rotarod test.
Enhanced the activation of the PI3K/Akt/CREB/BDNF axis.
Increased pERK_1/2 levels, attenuated neuroinflammatory and oxidative stress status.
Reduced the immunoreactivity of glial fibrillary acidic protein (GFAP).
Increased the number of intact neurons in the striatum.

Chemical Information

CAS. Nr. 36396-99-3
Appearance Solid
Molecular Weight 349.38
Formel C₁₆H₂₃N₅O₄
Color White to off-white
SMILES

OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCCC4)O1)O)O
Synonyms

CHA
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

Nature

Adenosine signalling drives antidepressant actions of ketamine and ECT. [Abstract]

2026 Jan;649(8096):423-431. PMID: 41193806
Int J Mol Sci

Torpor-like Hypothermia Induced by A1 Adenosine Receptor Agonist: A Novel Approach to Protect against Neuroinflammation. [Abstract]

2023 Jul 3;24(13):11036. PMID: 37446216
Exp Brain Res

Adenosine receptor A1 enhanced mitochondrial biogenesis and exerted neuroprotection after cerebral ischemia through PGC-1α. [Abstract]

2023 Jun;241(6):1471-1488. PMID: 37081178

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (286.22 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8622 mL

14.3111 mL

28.6221 mL

5 mM

0.5724 mL

2.8622 mL

5.7244 mL

10 mM

0.2862 mL

1.4311 mL

2.8622 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Asghari AA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies. J Neurol Sci. 2013 Feb 15;325(1-2):22-28. [Content Brief]

[2]. Blanco-Centurion C, et al. Adenosine and sleep homeostasis in the Basal forebrain. J Neurosci. 2006 Aug 2;26(31):8092-100. [Content Brief]

[3]. Nikodijević O, et al. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 1990 Feb 12;261(1):67-70. [Content Brief]

[4]. Nakashima J, et al. Increased erythropoietin secretion in human hepatoma cells by N6-cyclohexyladenosine. Am J Physiol. 1991 Sep;261(3 Pt 1):C455-60. [Content Brief]

[5]. Churchill PC, et al. Renin secretory effects of N6-cyclohexyladenosine: effects of dietary sodium. Am J Physiol. 1987 May;252(5 Pt 2):F872-6. [Content Brief]

[6]. Rabie MA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model. Chem Biol Interact. 2023 Jan 5;369:110288. [Content Brief]

[7]. Liddle LJ, et al. An Assessment of Physical and N6-Cyclohexyladenosine-Induced Hypothermia in Rodent Distal Focal Ischemic Stroke. Ther Hypothermia Temp Manag. 2024 Mar;14(1):36-45. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8622 mL	14.3111 mL	28.6221 mL	71.5553 mL
	5 mM	0.5724 mL	2.8622 mL	5.7244 mL	14.3111 mL
	10 mM	0.2862 mL	1.4311 mL	2.8622 mL	7.1555 mL
	15 mM	0.1908 mL	0.9541 mL	1.9081 mL	4.7704 mL
	20 mM	0.1431 mL	0.7156 mL	1.4311 mL	3.5778 mL
	25 mM	0.1145 mL	0.5724 mL	1.1449 mL	2.8622 mL
	30 mM	0.0954 mL	0.4770 mL	0.9541 mL	2.3852 mL
	40 mM	0.0716 mL	0.3578 mL	0.7156 mL	1.7889 mL
	50 mM	0.0572 mL	0.2862 mL	0.5724 mL	1.4311 mL
	60 mM	0.0477 mL	0.2385 mL	0.4770 mL	1.1926 mL
	80 mM	0.0358 mL	0.1789 mL	0.3578 mL	0.8944 mL
	100 mM	0.0286 mL	0.1431 mL	0.2862 mL	0.7156 mL

Keywords

N6-Cyclohexyladenosine

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

N6-Cyclohexyladenosine

Epigenetics Compound Library

GPCR/G Protein Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) N6-Cyclohexyladenosine

Alle Adenosine Receptor Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

N6-Cyclohexyladenosine Related Classifications

HY-18939 Related Classifications